PedAM
Pediatric Disease Annotations & Medicines
| Disease | thromboembolism |
| Phenotype | C0085278|antiphospholipid syndrome |
| Sentences | 8 |
| PubMedID- 23740031 | Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. |
| PubMedID- 25043836 | New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. |
| PubMedID- 22635217 | Secondary prevention of venous thromboembolism in antiphospholipid syndrome (aps) is usually made using vitamin k antagonists (vkas) to maintain an international normalized ratio (inr) between 2.0 and 3.0. |
| PubMedID- 25118790 | Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. |
| PubMedID- 20353992 | Anticoagulation with oral vitamin k antagonists (vka) is the mainstay of the treatment of venous and/or arterial thromboembolism in patients with antiphospholipid syndrome (aps), although the optimal intensity of anticoagulation remains controversial. |
| PubMedID- 21692222 | Hereditary trombophilia and antiphospholipid syndrome increase the risk of complications of venous thromboembolism significantly. |
| PubMedID- 23304562 | Preemptive analgesia could probably play a role in the clinical setting of this patient [8–11]; however nsaids carry the risk of precipitating thromboembolic events to patients with antiphospholipid syndrome [6] while gabapentin may eventually deteriorate the underlying neurological pathology. |
| PubMedID- 21511804 | One had a basilic vein thrombosis that was thought to have an anatomical cause; the remaining three had confirmed venous thromboembolism with predisposing conditions (antiphospholipid syndrome, major trauma, prolonged immobility). |
Page: 1